Inflammation  >>  Tecentriq (atezolizumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

16 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Tecentriq (atezolizumab) / Roche
QUILT-3.055, NCT03228667: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors

Checkmark For relapsed NSCLC based on QUILT-3.055 study
Jan 2021 - Jan 2021: For relapsed NSCLC based on QUILT-3.055 study
Active, not recruiting
2b
147
US
N-803 + Pembrolizumab, N-803 + Nivolumab, N-803 + Atezolizumab, N-803 + Avelumab, N-803 + Durvalumab, N-803 + Pembrolizumab + PD-L1 t-haNK, N-803 + Nivolumab + PD-L1 t-haNK, N-803 + Atezolizumab + PD-L1 t-haNK, N-803 + Avelumab + PD-L1 t-haNK, N-803 + Durvalumab + PD-L1 t-haNK
ImmunityBio, Inc.
Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Urothelial Carcinoma, Head and Neck Squamous Cell Carcinoma, Merkel Cell Carcinoma, Melanoma, Renal Cell Carcinoma, Gastric Cancer, Cervical Cancer, Hepatocellular Carcinoma, Microsatellite Instability, Mismatch Repair Deficiency, Colorectal Cancer
05/24
12/24
NCT04997382: Immunochemotherapy or Chemotherapy in ALK-rearranged 5'-ALK NSCLC

Completed
2
108
RoW
Chemotherapy alone or Chemotherapy plus Immune Checkpoint Inhibitors with or without Bevacizumab, Bevacizumab, Chemotherapy alone or Chemotherapy with or without Bevacizumab
Hunan Province Tumor Hospital
Non-small Cell Lung Cancer
01/24
01/24
RamAtezo-1, NCT03689855: Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC

Completed
2
21
US
Ramucirumab, Cyramza, Atezolizumab, Tecentriq, Peripheral blood draw, Biopsy
Washington University School of Medicine, Eli Lilly and Company
Non-small Cell Lung Cancer, Non Small Cell Lung Cancer, NSCLC
07/21
04/24
NCT03544723: Safety and Efficacy of p53 Gene Therapy Combined With Immune Checkpoint Inhibitors in Solid Tumors.

Recruiting
2
40
US
Ad-p53, anti-PD-1/anti-PD-L1, nivolumab, pembrolizumab, atezolizumab, durvalumab
MultiVir, Inc.
Solid Tumor, Lymphoma
06/22
12/22
NCT05456165: Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer

Terminated
2
1
US
GRT-C901, GRT-R902, Atezolizumab, Ipilimumab, Adjuvant chemotherapy
Gritstone bio, Inc.
Colonic Neoplasms, Colorectal Neoplasms
09/22
09/22
ABACUS-2, NCT04624399 / 2019-004628-39: Neoadjuvant Immune Checkpoint Inhibitor Treatment in Urothelial Cancer

Recruiting
2
58
Europe
Atezolizumab, MPDL3280A
Queen Mary University of London, Hoffmann-La Roche
Urogenital Cancer
07/23
12/24
NCT03693014: A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors

Recruiting
2
60
US
Stereotactic Body Radiotherapy, Ipilimumab, Nivolumab, Pembrolizumab or Atezolizumab
Memorial Sloan Kettering Cancer Center
Metastatic Cancer, Melanoma Cancer, Lung Cancer, Bladder Cancer, Renal Cancer, Head/Neck Cancers
10/25
10/25
RAN, NCT05007769: Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC

Withdrawn
2
0
NA
Ramucirumab, Cyramza, Atezolizumab, Tecentriq, N-803
Washington University School of Medicine, Eli Lilly and Company, ImmunityBio, Inc.
Non-small Cell Lung Cancer, Non-small Cell Carcinoma, NSCLC, Non Small Cell Lung Cancer
04/24
04/26
ATEZOLACC, NCT03612791 / 2017-003622-33: Trial Assessing the Inhibitor of Programmed Cell Death Ligand 1 (PD-L1) Immune Checkpoint Atezolizumab

Active, not recruiting
2
189
Europe
Atezolizumab, Radiotherapy, Cisplatin
Gustave Roussy, Cancer Campus, Grand Paris
Locally Advanced Cervical Cancer
02/24
04/25
SAKK 17/18, NCT04480372: (ORIGIN) MPM & NSCLC >1st Line Gemci & Atezo Ph II

Completed
2
68
Europe
Gemcitabine, Atezolizumab
Swiss Group for Clinical Cancer Research
Malignant Pleural Mesothelioma, Non-small Cell Lung Cancer
03/23
04/24
SIRTCI, NCT04659382: Study to Evaluate Efficacy and Safety of Selective Internal Radiation Therapy Plus Xelox, Bevacizumab and Atezolizumab (Immune Chekpoint Inhibitor) in Patients With Liver-dominant Metastatic Colorectal Cancer

Recruiting
2
52
Europe
Atezolizumab, Therasphere, XELOX, Bevacizumab
Federation Francophone de Cancerologie Digestive
Metastatic Colorectal Cancer, pMMR, MSS, Immune Checkpoint Inhibitor, Internal Radiotherapy
10/24
10/24
Stereosarc, NCT03548428: Stereotaxic Body Irradiation of Oligometastase in Sarcoma

Recruiting
2
103
Europe
Atezolizumab, SBRT, High Dose Radiation
Centre Antoine Lacassagne, Centre Hospitalier Universitaire de Caen, Roche Pharma AG
Sarcoma, Radiosurgery
07/25
12/27
ANTONIO, NCT05118724: Atezolizumab in Patients With MSI-h/MMR-D Stage III Colorectal Cancer Ineligible for Oxaliplatin

Recruiting
2
80
Europe
Atezolizumab, Tecentriq
AIO-Studien-gGmbH, Roche Pharma AG, Immodulon Therapeutics Ltd
Colorectal Cancer
11/26
11/26
NCI-2016-01233, NCT02935361: Guadecitabine and Atezolizumab in Treating Patients With Advanced Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia That Is Refractory or Relapsed

Active, not recruiting
1/2
33
US
Atezolizumab, MPDL 3280A, MPDL 328OA, MPDL-3280A, MPDL3280A, MPDL328OA, RG7446, RO5541267, Tecentriq, Guadecitabine, DNMT inhibitor SGI-110, S110, SGI-110
University of Southern California, National Cancer Institute (NCI), Van Andel Research Institute
Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia With Myelodysplasia-Related Changes
11/24
11/25
MEKiAUTO, NCT04214418: Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies

Active, not recruiting
1/2
175
US
Cobimetinib, Hydroxychloroquine, Atezolizumab, TECENTRIQ, MPDL3280A
Columbia University, Genentech, Inc.
Gastrointestinal Cancer
06/24
09/24
NCT04691817: Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy

Recruiting
1/2
28
US
Atezolizumab, Tecentriq, Tocilizumab, Actemra, RoActemra, RO4877533
Abramson Cancer Center at Penn Medicine, Genentech, Inc.
Lung Cancer, Nonsmall Cell
12/25
09/26

Download Options